Mar
24
2021
On demand

FectoVIR®-AAV, the new tool to enhance recombinant AAV production for gene therapy

Ever-increasing demand for clinical and commercial-scale recombinant adeno-associated viral (rAAV) vector manufacturing has brought into sharp focus the need for new technological innovation to drive the requisite bioprocess productivity and efficiency gains.    

In this webinar, Viralgen - a CDMO born as a joint venture between Askbio and Columbus Venture Partners, and recently acquired by Bayer - will discuss its approach to driving the industrialization of rAAV vector production, and present recent data obtained with the FectoVIR®-AAV transfection reagent for the production of rAAV in its Pro10™ cell line.

Attendees will learn:

  • How to optimize AAV productions based on improved transfection tools.
  • How to improve transfection reproducilbility and rAAv production at different production scales.

Mathieu Porte

Bioproduction R&D Manager, Polyplus-transfection®

Mathieu Porte is Bioproduction R&D Manager at Polyplus-transfection®. After obtaining his Biotechnology Engineering Degree from the renowned European School ESBS (Strasbourg, France), he worked as Research Assistant at New England Biolabs and UCSF. He joined Polyplus-transfection® in 2009. During 10 years in the Bioproduction R&D group, he carried out the development of several innovative transfection solutions dedicated to biomanufacturing.

Valerie Lang

USP Manager, Viralgen VC

Valerie Lang is USP Manager at Viralgen Vector Core. She obtained her PhD in molecular and cellular pharmacology in the University of Pierre and Marie Curie (Paris, France). She has extensive experience in cell culture and manufacturing. She joined Viralgen in 2017 and has been responsible for designing, implementing, and optimizing industrial AAV processes and manufacturing.

Elisa Da Silva Ferrada

Upstream Process Development Lead Scientist, Viralgen VC

Elisa da Silva Ferrada is USP Process Development Lead Scientist at Viralgen Vector Core (VVC). Got her PhD at University of Basque Country in Molecular Biology and Biomedicine. Joined to VVC in 2019 to work on USP process development for AAV production


SPEAKERS

Mathieu Porte
BioProduction R&D Manager, Polyplus-transfection
Elisa Da Silva Ferrada
USP Process Development Lead Scientist, Viralgen Vector Core (VVC)
Valerie Lang
Production Manger, Viralgen VC

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
35
Days
5
Hrs
57
Min
Register

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
13
Hrs
57
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
27
Days
5
Hrs
57
Min
Register

Taking a right first-time approach to optimize end-to-end viral vector...

H Lesch
J Depollier
Hanna Lesch
Hanna Lesch
Chief Technology Officer at Exothera
Julien Depollier
Julien Depollier
Business Director, Americas at Polyplus-transfection
9 Jun 2022
22
Days
5
Hrs
57
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
20
Days
5
Hrs
57
Min
Register